Literature DB >> 28905085

[Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].

S C Brandelik1, J Krzykalla2, T Hielscher2, J Hillengass3, J K Kloth4, H U Kauczor5, M A Weber5,6.   

Abstract

BACKGROUND AND OBJECTIVES: In this study, we evaluated methods of quantification of tumor mass in whole-body MRI (wb-MRI) in multiple myeloma and correlated these with disease-related parameters in serum and bone marrow.
MATERIALS AND METHODS: We retrospectively evaluated wb-MRIs of 52 patients with focal infiltration pattern and a total of 700 focal lesions (subsequently called lesions). We determined the longest diameter (LD), the segmented volume (SV), and the morphology (spherical or non-spherical). We correlated total number/volume of the lesions with clinical parameters and prognosis and furthermore LD with SV. After that we analyzed the agreement of SV and estimated volume (EV) using the volume formula of a sphere based on LD.
RESULTS: Results showed no significant correlations of total number/volume with prognosis or clinical parameters. The latter were situated predominantly in the normal range. Furthermore, 10% of lesions were spherical. SV and LD correlated significantly in single lesions and on patient level. SV was in lesions <6 cm3 systematically larger and in lesions ≥6 cm3 smaller than EV. In 95%, we found in small lesions a deviation of EV versus SV from +0.9 cm3 to -4.6 cm3 and in large lesions from +160 cm3 to -111 cm3 (EV-SV).
CONCLUSIONS: Quantification of tumor mass in the focal infiltration pattern is performed more accurately by volumetry than LD due to the predominant existence of non-spherical lesions. The patient cohort with clinical parameters predominantly in the normal range is distributed to ISS stage I and partly pretreated, a fact that makes interpretation of absent correlations more difficult. Consider also a variation in activitiy of lesions and a diffuse infiltration not detectable by MRI.

Entities:  

Keywords:  Focal lesions; Plasma cell disease; Segmentation; Tumor burden; Volumetry

Mesh:

Year:  2018        PMID: 28905085     DOI: 10.1007/s00117-017-0299-7

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  32 in total

1.  Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Authors:  Jens Hillengass; Kerstin Fechtner; Marc-André Weber; Tobias Bäuerle; Sofia Ayyaz; Christiane Heiss; Thomas Hielscher; Thomas M Moehler; Gerlinde Egerer; Kai Neben; Anthony D Ho; Hans-Ulrich Kauczor; Stefan Delorme; Hartmut Goldschmidt
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

2.  MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.

Authors:  Savannah C Partridge; Jessica E Gibbs; Ying Lu; Laura J Esserman; Debasish Tripathy; Dulcy S Wolverton; Hope S Rugo; E Shelley Hwang; Cheryl A Ewing; Nola M Hylton
Journal:  AJR Am J Roentgenol       Date:  2005-06       Impact factor: 3.959

3.  Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates.

Authors:  A Stäbler; A Baur; R Bartl; R Munker; R Lamerz; M F Reiser
Journal:  AJR Am J Roentgenol       Date:  1996-10       Impact factor: 3.959

4.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

5.  Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma.

Authors:  Jens Hillengass; Sofia Ayyaz; Kerstin Kilk; Marc-André Weber; Thomas Hielscher; Rajiv Shah; Dirk Hose; Stefan Delorme; Hartmut Goldschmidt; Kai Neben
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

6.  Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.

Authors:  Shaji Kumar; Rafael Fonseca; Rhett P Ketterling; Angela Dispenzieri; Martha Q Lacy; Morie A Gertz; Suzanne R Hayman; Francis K Buadi; David Dingli; Ryan A Knudson; Alexandra Greenberg; Stephen J Russell; Steven R Zeldenrust; John A Lust; Robert A Kyle; Leif Bergsagel; S Vincent Rajkumar
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

7.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

8.  Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.

Authors:  Sikander Ailawadhi; Ahmed N Abdelhalim; Lyudmyla Derby; Terry L Mashtare; Kena C Miller; Gregory E Wilding; Ronald A Alberico; Ronald Gottlieb; Donald L Klippenstein; Kelvin Lee; Asher A Chanan-Khan
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

9.  Contrast enhanced MRI and ¹⁸F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease.

Authors:  P Spinnato; A Bazzocchi; A Brioli; C Nanni; E Zamagni; U Albisinni; M Cavo; S Fanti; G Battista; E Salizzoni
Journal:  Eur J Radiol       Date:  2012-08-24       Impact factor: 3.528

10.  Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.

Authors:  Jost K Kloth; Jens Hillengass; Karin Listl; Kerstin Kilk; Thomas Hielscher; Ola Landgren; Stefan Delorme; Hartmut Goldschmidt; Hans-Ulrich Kauczor; Marc-André Weber
Journal:  Int J Cancer       Date:  2014-04-17       Impact factor: 7.396

View more
  1 in total

1.  Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients.

Authors:  Markus Wennmann; Laurent Kintzelé; Marie Piraud; Bjoern H Menze; Thomas Hielscher; Johannes Hofmanninger; Barbara Wagner; Hans-Ulrich Kauczor; Maximilian Merz; Jens Hillengass; Georg Langs; Marc-André Weber
Journal:  Oncotarget       Date:  2018-05-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.